Naquotinib

DB12036InvestigationalSmall molecule

Naquotinib has been used in trials studying the treatment of Solid Tumors, Non-small Cell Lung Cancer, Non-Small-Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor Mutations, and Epidermal Growth Factor Receptor...

Mechanism: Pharmacologically active on Epidermal growth factor receptor
Curator reviewed
Formula / weight: C₃₀H₄₂N₈O₃ · 562.719 g/mol (avg)
Code names: ASP-8273

Resolves to

Compound

UNII47DD4548PBCAS1448232-80-1ChEMBLCHEMBL3663929PubChem71667668

Structure

InChIKeyQKDCLUARMDUUKN-XMMPIXPASA-NSMILESCCC1=C(O[C@@H]2CCN(C2)C(=O)C=C)N=C(NC2=CC=C(C=C2)N2CCC(CC2)N2CCN(C)CC2)C(=N1)C(N)=O

Targets

P00533EGFR

What you can answer from here — as of September 16, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

7Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Naquotinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account